Navigation Links
drugstore.com inc. Reports Results for the First Quarter of 2008
Date:5/5/2008

$2,076 $1,891

SUPPLEMENTAL INFORMATION: Gross Profit and Gross Margin Information:

Three Months Ended

March 30, April 1,

(In thousands, unless otherwise indicated) 2008 2007

Net sales $120,637 $109,765

Cost of sales 91,723 85,062

Gross profit $28,914 $24,703

Gross margin 24.0% 22.5%

SUPPLEMENTAL INFORMATION: Reconciliation of OTC net sales, cost of sales,

gross profit, gross margin, variable order costs, and contribution margin

to Core OTC net sales, cost of sales, gross profit, gross margin, variable

order costs and contribution margin (See Note 3 below):

Three Months Ended

March 30, April 1,

2008 2007

(In thousands)

Over-the-Counter (OTC):

Net sales $64,851 $56,262

CNS 476 503

Core OTC net sales $64,375 $55,759

Cost of sales $45,013 $39,651

CNS 37 27

Core OTC cost of sales $44,976 $39,624

Gross profit 19,838 16,611

CNS 439 476

Core OTC gross profit $19,399
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. drugstore.com, inc. to Announce First Quarter 2008 Results During Conference Call on Monday, May 5, 2008 at 5:00 p.m. ET
2. drugstore.com, inc. to Present at the Upcoming Jefferies 4th Annual Internet Conference and the Morgan Stanley Technology Conference
3. drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
4. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
5. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
6. drugstore.com and Revolution Health Group Announce Breakthrough Deal
7. BELLUS HEALTH reports results for first quarter of fiscal 2008
8. Genetic Engineering and Biotechnology News reports on early ADMET use
9. EntreMed Reports First Quarter 2008 Financial Results
10. Cepheid Reports Record Revenue of $44.8 Million
11. Cephalon Reports Strong First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , ... July 28, 2015 , ... Egg freezing ... the procedure to help ensure future fertility. As Dr. Michael Kettel explained ... freezing is an option that wasn’t available for previous generations who had to make ...
(Date:7/28/2015)... ... July 28, 2015 , ... BMI of Texas, which specializes ... duodenal switch weight loss surgery procedure. Committed to helping patients achieve their ... BMI of Texas is one of the first practices in South Texas ...
(Date:7/28/2015)... Angeles, CA (PRWEB) , ... July 28, 2015 , ... ... highs several times a day to a few times a year. The World Health ... research study by the National Institute of Mental Health reveals that the United States ...
(Date:7/28/2015)... Fayetteville, Arkansas (PRWEB) , ... July 28, 2015 ... ... discovery company developing targeted biologics and biologic-device combination products for the treatment of ... Trademark Office issued U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain ...
(Date:7/28/2015)... ... July 28, 2015 , ... Care ... proprietary, web based clinical knowledge system, called “Referral Guidance.” , Referral ... provides physicians who are anticipating making a subspecialty referral an efficient means to ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 2Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2
... Over the counter (OTC) drugs can be highly addictive, warn ... ,The development of dependency on OTC drugs is often forgotten, ... past three months, they describe seeing three patients with addictions ... three had started using the product for its approved indications, ...
... cancer research study that may be the last best chance ... to discover the genetic and environmental factors that cause and ... aims to enroll a geographically and ethnically diverse group of ... pave the way for the next generation of American Cancer ...
... such as endometriosis, but it is also being proposed ... menstruation or find it inconvenient. ,But ... lifestyle choice, asks Paula Derry, a Health Psychologist in ... reduce or eliminate periods are being developed, she writes. ...
... if neglected, specialists warn. Most of us brush ... is harmless. But specialists say it could lead to chronic ... or cause harm to any part of the brain. ... because of unchecked pollution. Chronic sinus may also be caused ...
... in The American Journal of Gastroenterology suggests that smoking ... attacked in those who suffer from Crohns disease. ... patient will eventually require surgical treatment. ,In ... frequently in the small intestine, rather than the colon, ...
... Britons may just feel the heart in their mouth when they ... of suffering a heart attack have finally been identified by ... shown that one fifth of Britons carry a particular gene which ... grace could come in the form of making healthy lifestyle choices ...
Cached Medicine News:Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Should Menstrual Suppression Be a Lifestyle Choice? 2Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:The DNA That Spells Double Risk of Heart Attack 2
(Date:7/28/2015)... , July 28, 2015 Mike Rowe , ... at Good Neighbor Pharmacy,s 2015 ThoughtSpot ... 1 in Las Vegas, Nev. ... "Somebody,s Gotta Do It," and Discovery Channel,s, "Dirty Jobs," Mr. ... the nation,s  "unsung heroes" – people whose hard work, sacrifice ...
(Date:7/28/2015)... , July 28, 2015  Today, Sekisui Diagnostics announces ... affordable and efficient instrument, with a broad menu of ... benefits to the physicians, office or hospital laboratory. ... to 580 tests/hour with ISE, 72 patient sample on-board ... 36 onboard assays (+3 ISE) to meet the testing ...
(Date:7/28/2015)... VirtualScopics, Inc. (NASDAQ: VSCP ), a ... that it will report its second quarter 2015 financial ... Tuesday, August 11, 2015.  Eric T. Converse , ... , chief financial officer, will host a conference call ... provide a business update at 4:30 p.m. ET that ...
Breaking Medicine Technology:Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2Sekisui Diagnostics Announces Launch of SK500 Clinical Chemistry System for US Laboratories 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3
... LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Urological,Association (AUA) Annual Meeting, which is currently taking ... Dr. Timothy A.,Yap from the Cancer Research UK ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: